A randomized, double-blind, placebo-controlled, dose-ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and the pharmacokinetics of GSK221149A administered orally...

...in healthy, pregnant females with incomplicated pre-term labor between 300/7-356/7 weeks gestation

Sponsor

SmithKline Beecham Pharmaceuticals

Principal Investigator

Dr. John Thorp, Obstetrics and Gynecology

Project Run Dates

8/25/2009 to 8/24/2012

 

Summary

None